NK-062

NK-062 is a preclinical-stage natural killer (NK) cell therapy being developed by Shanghai NK Cell Technology (also known as NK CellTech). It is part of the company's NKR-NK+ platform, which involves engineering NK cells with specific NK cell receptors (NKR) to enhance their tumor-targeting capabilities. The therapy is developed using synthetic immunology technologies, including logic circuits, feedback switches, and intelligent control systems, to create quantified and controlled cellular responses. While intended for the treatment of unspecified tumors, specific molecular targets and detailed mechanisms of action for NK-062 have not been publicly disclosed by the developer.